Skip to main content
. 2022 Dec 22;9:1071732. doi: 10.3389/fmed.2022.1071732

FIGURE 8.

FIGURE 8

Description of (A) the median glucocorticoid (prednisone or equivalent) intake as mg/day at the start of canakinumab and at each follow-up visit, distinguishing according to the different disease pattern (systemic versus chronic-articular); (B) the total number of patients administered glucocorticoids (GC) at the different timepoints; (C) the total number of patients administered methotrexate (MTX) at the different timepoints.